دورية أكاديمية
أعرض في EDS

Impact of Opioid Use on Duration of Therapy and Overall Survival for Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.

التفاصيل البيبلوغرافية
العنوان: Impact of Opioid Use on Duration of Therapy and Overall Survival for Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
المؤلفون: Young P; Department of Medicine, Division of Hematology/Oncology, University of Virginia, Charlottesville, VA 22903, USA., Elghawy O; School of Medicine, University of Virginia, Charlottesville, VA 22903, USA., Mock J; Department of Medicine, Division of Hematology/Oncology, University of Virginia, Charlottesville, VA 22903, USA., Wynter E; Department of Medicine, University of Virginia, Charlottesville, VA 22903, USA., Gentzler RD; Department of Medicine, Division of Hematology/Oncology, University of Virginia, Charlottesville, VA 22903, USA., Martin LW; Department of Surgery, Division of Thoracic and Cardiovascular Surgery, University of Virginia, Charlottesville, VA 22903, USA., Novicoff W; Department of Public Health Sciences and Orthopedic Surgery, University of Virginia, Charlottesville, VA 22903, USA., Hall R; Department of Medicine, Division of Hematology/Oncology, University of Virginia, Charlottesville, VA 22903, USA.
المصدر: Current oncology (Toronto, Ont.) [Curr Oncol] 2024 Jan 03; Vol. 31 (1), pp. 260-273. Date of Electronic Publication: 2024 Jan 03.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 9502503 Publication Model: Electronic Cited Medium: Internet ISSN: 1718-7729 (Electronic) Linking ISSN: 11980052 NLM ISO Abbreviation: Curr Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2021- : Basel, Switzerland : MDPI
Original Publication: Toronto : Multimed, c1994-
مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Lung Neoplasms*/drug therapy , Opioid-Related Disorders*, Humans ; Analgesics, Opioid/therapeutic use ; Immune Checkpoint Inhibitors ; Duration of Therapy
مستخلص: Immune checkpoint inhibitors (ICI) have significantly improved outcomes in advanced non-small cell lung cancer (NSCLC). We evaluated the effect of opioid use on outcomes in patients receiving ICI either alone or with chemotherapy. We conducted a retrospective review of 209 patients with advanced NSCLC who received an ICI at the University of Virginia between 1 February 2015 and 1 January 2020. We performed univariate and multivariate analyses to evaluate the impact of opioid use on duration of therapy (DOT) and overall survival (OS). Patients with no or low opioid use (n = 172) had a median DOT of 12.2 months (95% CI: 6.9-17.4) compared to 1.9 months (95% CI: 1.8-2.0) for those with high opioid use (n = 37, HR 0.26 95% CI: 0.17-0.40, p < 0.001). Patients with no or low opioid use had a median OS of 22.6 months (95% CI: 14.8-30.4) compared to 3.8 months (95% CI: 2.7-4.9) for those with high opioid use (HR 0.26 95% CI: 0.17-0.40 p < 0.001). High opioid use was associated with a shorter DOT and worse OS. This difference remained significant when accounting for possible confounding variables. These data warrant investigation of possible mechanistic interactions between opioids, tumor progression, and ICIs, as well as prospective evaluation of opioid-sparing pain management strategies, where possible.
References: Mucosal Immunol. 2016 Nov;9(6):1418-1428. (PMID: 26906406)
Cancer. 2013 Dec 1;119(23):4103-10. (PMID: 24104703)
Healthcare (Basel). 2022 Dec 30;11(1):. (PMID: 36611575)
Eur J Pharmacol. 2021 Sep 5;906:174284. (PMID: 34174268)
N Engl J Med. 2016 Nov 10;375(19):1823-1833. (PMID: 27718847)
Front Pharmacol. 2017 Aug 23;8:561. (PMID: 28878676)
Br J Anaesth. 2014 Oct 10;113(Suppl 1):i109-i116. (PMID: 25303989)
Ann Oncol. 2016 Nov;27(11):2032-2038. (PMID: 27573565)
Br J Pharmacol. 2018 Jul;175(14):2717-2725. (PMID: 28213891)
J Clin Oncol. 2021 Jul 20;39(21):2339-2349. (PMID: 33872070)
N Engl J Med. 2018 Jun 14;378(24):2288-2301. (PMID: 29863955)
Anesthesiology. 2012 Apr;116(4):857-67. (PMID: 22343475)
PLoS One. 2014 Mar 24;9(3):e91577. (PMID: 24662916)
Br J Anaesth. 2014 Jul;113 Suppl 1:i103-8. (PMID: 24920011)
Lancet Oncol. 2021 Feb;22(2):198-211. (PMID: 33476593)
Clin Transl Oncol. 2020 Sep;22(9):1481-1490. (PMID: 31919759)
N Engl J Med. 2018 Nov 22;379(21):2040-2051. (PMID: 30280635)
Anesth Analg. 2011 Dec;113(6):1353-64. (PMID: 22003224)
Sci Rep. 2017 Jun 15;7(1):3628. (PMID: 28620208)
Cancers (Basel). 2022 Apr 30;14(9):. (PMID: 35565382)
Ann Thorac Surg. 2021 Jun;111(6):1791-1798. (PMID: 33127403)
Cancer Discov. 2018 Sep;8(9):1069-1086. (PMID: 30115704)
PLoS One. 2018 Mar 29;13(3):e0194171. (PMID: 29596446)
Front Immunol. 2022 May 06;13:861723. (PMID: 35603146)
JAMA Netw Open. 2021 Jul 1;4(7):e2117547. (PMID: 34309669)
J Clin Oncol. 2020 May 10;38(14):1505-1517. (PMID: 32150489)
J Thorac Oncol. 2020 Oct;15(10):1657-1669. (PMID: 32599071)
J Clin Oncol. 2002 Oct 1;20(19):4040-9. (PMID: 12351602)
Lancet Oncol. 2016 Nov;17(11):1497-1508. (PMID: 27745820)
BMJ Support Palliat Care. 2023 Oct;13(e1):e185-e189. (PMID: 33293293)
JAMA Oncol. 2019 Dec 1;5(12):1774-1778. (PMID: 31513236)
N Engl J Med. 2019 Nov 21;381(21):2020-2031. (PMID: 31562796)
N Engl J Med. 2018 May 31;378(22):2078-2092. (PMID: 29658856)
Br J Pharmacol. 2018 Jul;175(14):2726-2736. (PMID: 28593737)
Science. 2018 Jan 5;359(6371):91-97. (PMID: 29097494)
Int Immunol. 2016 Aug;28(8):401-9. (PMID: 27160722)
MMWR Recomm Rep. 2022 Nov 04;71(3):1-95. (PMID: 36327391)
Int J Immunopharmacol. 1995 Dec;17(12):1001-6. (PMID: 8964649)
J Palliat Med. 2018 Oct;21(10):1436-1441. (PMID: 29893612)
فهرسة مساهمة: Keywords: duration of therapy; immune checkpoint inhibitors; non-small cell lung cancer; opioids; overall survival
المشرفين على المادة: 0 (Analgesics, Opioid)
0 (Immune Checkpoint Inhibitors)
تواريخ الأحداث: Date Created: 20240122 Date Completed: 20240123 Latest Revision: 20240524
رمز التحديث: 20240524
مُعرف محوري في PubMed: PMC10814484
DOI: 10.3390/curroncol31010017
PMID: 38248102
قاعدة البيانات: MEDLINE
الوصف
تدمد:1718-7729
DOI:10.3390/curroncol31010017